MA25509A1 - Composition destinee au traitement de l'hepatite c - Google Patents

Composition destinee au traitement de l'hepatite c

Info

Publication number
MA25509A1
MA25509A1 MA26657A MA26657A MA25509A1 MA 25509 A1 MA25509 A1 MA 25509A1 MA 26657 A MA26657 A MA 26657A MA 26657 A MA26657 A MA 26657A MA 25509 A1 MA25509 A1 MA 25509A1
Authority
MA
Morocco
Prior art keywords
hepatitis
treatment
composition
Prior art date
Application number
MA26657A
Other languages
English (en)
Inventor
Wassyl Nowicky
Original Assignee
Nowicky Wassili
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nowicky Wassili filed Critical Nowicky Wassili
Publication of MA25509A1 publication Critical patent/MA25509A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA26657A 2000-03-22 2002-05-28 Composition destinee au traitement de l'hepatite c MA25509A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0048100A AT408719B (de) 2000-03-22 2000-03-22 Mittel zur behandlung von hepatitis c

Publications (1)

Publication Number Publication Date
MA25509A1 true MA25509A1 (fr) 2002-07-01

Family

ID=3674939

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26657A MA25509A1 (fr) 2000-03-22 2002-05-28 Composition destinee au traitement de l'hepatite c

Country Status (17)

Country Link
JP (1) JP2003527414A (fr)
KR (1) KR20020087045A (fr)
CN (1) CN1416347A (fr)
AT (1) AT408719B (fr)
AU (1) AU2001239000A1 (fr)
BG (1) BG107088A (fr)
BR (1) BR0107211A (fr)
CA (1) CA2389173A1 (fr)
EA (1) EA200200584A1 (fr)
HR (1) HRP20020367A2 (fr)
IL (1) IL149314A0 (fr)
IS (1) IS6360A (fr)
MA (1) MA25509A1 (fr)
MX (1) MXPA02004993A (fr)
NO (1) NO20022253L (fr)
PL (1) PL365000A1 (fr)
WO (1) WO2001070203A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH695417A5 (de) * 2001-11-15 2006-05-15 Ddr Wassyl Nowicky Dipl Ing Verfahren zur Umsetzung von Alkaloiden.
EP1459753A1 (fr) 2003-03-18 2004-09-22 Nowicky, Wassyl, Dipl.-Ing. DDr. Dérivés quaternaires de chelidonine et d'alkaloides, procédé pour leur préparation et leur utilisation dans la préparation de médicaments
CA2664935A1 (fr) * 2006-09-26 2008-04-03 Addiction Research Institute, Inc. Compositions de traitement de l'hepatite c et procedes d'utilisation des compositions de traitement de l'hepatite c
CN106343303A (zh) * 2015-07-13 2017-01-25 张如安 灭杀乙肝病毒的饮料
CN106109538A (zh) * 2016-07-29 2016-11-16 桂林淮安天然保健品开发有限公司 治疗丙肝的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3128018A1 (de) * 1981-07-13 1983-04-07 Wassyl 1060 Wien Nowicky "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
US4816462A (en) * 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
US4970212A (en) * 1982-05-18 1990-11-13 Nowicky Wassili Method of treating human illnesses which compromise the ability to mount an effective immunological response
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer

Also Published As

Publication number Publication date
HRP20020367A2 (en) 2004-02-29
IL149314A0 (en) 2002-11-10
KR20020087045A (ko) 2002-11-21
NO20022253D0 (no) 2002-05-10
WO2001070203A2 (fr) 2001-09-27
EA200200584A1 (ru) 2003-06-26
NO20022253L (no) 2002-05-10
ATA4812000A (de) 2001-07-15
BR0107211A (pt) 2004-01-06
CA2389173A1 (fr) 2001-09-27
PL365000A1 (en) 2004-12-27
CN1416347A (zh) 2003-05-07
AU2001239000A1 (en) 2001-10-03
JP2003527414A (ja) 2003-09-16
MXPA02004993A (es) 2003-10-14
BG107088A (en) 2003-05-30
IS6360A (is) 2002-04-24
AT408719B (de) 2002-02-25
WO2001070203A3 (fr) 2002-09-06

Similar Documents

Publication Publication Date Title
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
FR20C1039I2 (fr) Derives de l'uk-2a
EP1346724A4 (fr) Remedes pour l'hepatite c
MA27126A1 (fr) 3'PROMEDICAMENTS DE 2'-DESOXY- β-L-NUCLEOSIDES
EE200200716A (et) Ühendid Alzheimeri tõve käitluseks
CY2018020I2 (el) Θεραπεια της νοσου ρομρε
MA26207A1 (fr) Compositions de traitement de l'eau.
MA25823A1 (fr) Compositions pour le traitement de l'eau.
EP1165110A4 (fr) Antagonistes de hmg1 destines au traitement d'etats inflammatoires
ATE315938T1 (de) 4'-substituierte nukleoside zur behandlung von hepatitis-c-virus-vermittelten erkrankungen
EE05158B1 (et) 1,5-bensotiasepiinid ja nende kasutamine antilipideemiliste vahenditena
DE69912223D1 (de) Methylmethacrylat-Zusammensetzung
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
PT1250321E (pt) Composicao de gliburida
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
EP1240552A4 (fr) Compositions de photoresine aptes au traitement a l'eau
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
EP1357940A4 (fr) Traitement du virus de l'hepatite b
EE200200590A (et) Bradükardiaalsete toimeainete kasutamine hüpertroofiaga seotud müokardiaalsete haiguste ravimiseks ja uudsed ravimikombinatsioonid
EE200200632A (et) Glükokortikoidravimeid sisaldavad preparaadid bronhopulmonaalsete haiguste raviks
EP1161255A4 (fr) Procedes et compositions pour le traitement de la dyserection
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires